Clinical Trial

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Study acronym: LEVEL
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.
Protocol Amendment History 3 changes
notable Enrollment increased: 120 -> 170 participants 2026-05-13
notable Primary completion pushed: 2028-03 -> 2029-03 2026-05-13
minor Completion pushed: 2028-07 -> 2029-10 2026-05-13
Trial Details
NCT Number NCT05918302
Lead Sponsor Grupo Espanol de Tumores Neuroendocrinos
Collaborators: Lumara Bio Oncologics GmbH, MFAR
Conditions Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms
Enrollment 170 participants
Start Date 2023-10-27
Primary Completion 2029-03 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-12